Save time and money with
Med Tech Market Research


MedTech Business intelligence
supplied through Trade Tracker, Research and Markets and GlobalData

Commercial Insight: Top 20 Cancer Therapy Brands

Key brands set to consolidate advantage as competition intensifies

Publication Date:  August 2008
Publisher: Datamonitor
Pages: 40

Price £7,600.00
approximately: $13,400 | €9,422

Buy and download >>
(managed by Piribo)

Summary

Introduction

Cancer therapy brand sales totalled over $30 billion in the seven major markets in 2007, growing by 20.1% since 2006. The high growth of this market makes it attractive to companies keen to emulate the blockbuster status achieved by several brands. However, with several impending patent expiries due, companies will need to work hard to maximize their return throughout the lifecycle of their brands.

Scope

  • Current and future overview of the cancer therapy brands market in 2007 and 2017
  • Individual country forecasts for the Top 20 cancer therapy brands in each of the seven major markets
  • Segmentation and analysis of market dynamics by country sales, drug class, indication, company and impacted events
  • Detailed product profiles and discussion of assumptions and events used in forecast analysis

Highlights

The Top 20 cancer therapy brands in the seven major markets contributed the majority ($26.1 billion, 85%) of cancer therapy brand sales in 2007. Datamonitor forecasts the total market to grow to $62.4 billion by 2017 at a CAGR of 7%. The Top 20 brands in 2017 will still contribute a high proportion of this (80%) with sales reaching $50.2 billion.

Targeted therapies will increasingly dominate the Top 20 cancer brands leaderboard, accounting for 12 of the Top 20 brands in the seven major markets in 2017. Datamonitor forecasts Avastin to become the leading cancer therapy brand, facilitated by further indication expansion and high physician familiarity.

Genentech/Roche are the dominant force in the market with an oncology portfolio including the three leading cancer therapy brands (Rituxan, Avastin and Herceptin). The companies are set to continue this dominance, with Rituxan, Avastin and Herceptin forecast to remain the top three brands in 2017, achieving aggregate 7MM sales of over $23 billion.

Reasons to Purchase

  • Understand market specific drivers and predict the future potential of key cancer therapy brands.
  • Quantify the impact of key patent expiries and product launches and gain a valuable insight into the market dynamics.
  • Consider, assess and react to opportunities and risks influencing the leading cancer therapy brands.

Buy now >>

Content

  • About Datamonitor Healthcare
    • About The Oncology Pharmaceutical Analysis Team
  • Chapter 1 Executive Summary
    • Strategic Scoping And Focus
    • Datamonitor Insight Into The Cancer Therapy Brands Market
    • Related Reports
    • Upcoming Reports
  • Chapter 2 Market Definition
    • Definition Of The Cancer Market
    • Antihormonal Therapies By Atc Class
    • L2a3 - Luteinizing Hormone-Releasing Hormone Analogs
    • L2b1 - Anti-Estrogens
    • L2b2 - Anti-Androgens
    • L2b3 - Aromatase Inhibitors
    • Cytotoxic Therapies By Atc Class
    • L1a - Alkylating Agents
    • L1b - Antimetabolites
    • L1c - Vinca Alkaloids And Other Plant-Derived Products
    • L1d - Antineoplastic Antibiotics
    • L1x2 - Platinum Compounds
    • Report Classification Of Cytotoxic Therapies
    • Antimetabolites
    • Mitotic Inhibitors
    • Dna-Interactive Agents
    • Topoisomerase Poisons
    • Non-Covalent Dna Binding Drugs
    • Covalent Dna Binding Drugs - Alkylating Agents
    • Targeted Therapies By Atc Class
    • L1x3 - Antineoplastic Monoclonal Antibodies
    • L1x9 - All Other Antineoplastics
  • Chapter 3 Market Overview And Forecasts
    • Seven Major Markets
    • Current Market Assessment
    • Sales By Country - Total Market
    • Sales By Country - Top 20 Brands
    • Sales By Class - Total Market
    • Sales By Class - Top 20 Brands
    • Sales By Brand - Top 20 Brands
    • Future Market Assessment
    • Sales By Country - Total Market
    • Sales By Country - Top 20 Brands
    • Sales By Class - Total Market
    • Sales By Class - Top 20 Brands
    • Sales By Brand - Top 20 Brands
    • Opportunities And Threats
    • Opportunities
    • Threats
    • Us
    • Current Market Assessment
    • Sales By Class - Total Market
    • Sales By Class - Top 20 Brands
    • Sales By Brand - Top 20 Brands
    • Future Market Assessment
    • Sales By Class - Total Market
    • Sales By Class - Top 20 Brands
    • Sales By Brand - Top 20 Brands
    • Opportunities And Threats
    • Opportunities
    • Threats
    • Japan
    • Current Market Assessment
    • Sales By Class - Total Market
    • Sales By Class - Top 20 Brands
    • Sales By Brand - Top 20 Brands
    • Future Market Assessment
    • Sales By Class - Total Market
    • Sales By Class - Top 20 Brands
    • Sales By Brand - Top 20 Brands
    • Opportunities And Threats
    • Opportunities
    • Threats
    • 5eu
    • Current Market Assessment
    • Sales By Class - Total Market
    • Sales By Class - Top 20 Brands
    • Sales By Brand - Top 20 Brands
    • Future Market Assessment
    • Sales By Class - Total Market
    • Sales By Class - Top 20 Brands
    • Sales By Brand - Top 20 Brands
    • Opportunities And Threats
    • Opportunities
    • Threats
    • France
    • Current Market Assessment
    • Sales By Class - Total Market
    • Sales By Class - Top 20 Brands
    • Sales By Brand - Top 20 Brands
    • Future Market Assessment
    • Sales By Class - Total Market
    • Sales By Class - Top 20 Brands
    • Sales By Brand - Top 20 Brands
    • Opportunities And Threats
    • Opportunities
    • Threats
    • Germany
    • Current Market Assessment
    • Sales By Class - Total Market
    • Sales By Class - Top 20 Brands
    • Sales By Brand - Top 20 Brands
    • Future Market Assessment
    • Sales By Class - Total Market
    • Sales By Class - Top 20 Brands
    • Sales By Brand - Top 20 Brands
    • Opportunities And Threats
    • Opportunities
    • Threats
    • Italy
    • Current Market Assessment
    • Sales By Class - Total Market
    • Sales By Class - Top 20 Brands
    • Sales By Brand - Top 20 Brands
    • Future Market Assessment
    • Sales By Class - Total Market
    • Sales By Class - Top 20 Brands
    • Sales By Brand - Top 20 Brands
    • Opportunities And Threats
    • Opportunities
    • Threats
    • Spain
    • Current Market Assessment
    • Sales By Class - Total Market
    • Sales By Class - Top 20 Brands
    • Sales By Brand - Top 20 Brands
    • Future Market Assessment
    • Sales By Class - Total Market
    • Sales By Class - Top 20 Brands
    • Sales By Brand - Top 20 Brands
    • Opportunities And Threats
    • Opportunities
    • Threats
    • Uk
    • Current Market Assessment
    • Sales By Class - Total Market
    • Sales By Class - Top 20 Brands
    • Sales By Brand - Top 20 Brands
    • Future Market Assessment
    • Sales By Class - Total Market
    • Sales By Class - Top 20 Brands
    • Sales By Brand - Top 20 Brands
    • Opportunities And Threats
    • Opportunities
    • Threats
    • Rest Of World Snapshot
    • Global Cancer Therapies Market
    • Global Antihormonal Therapy Cancer Brands Market
    • Global Cytotoxic Therapy Cancer Brands Market
    • Global Targeted Therapy Cancer Brands Market
  • Chapter 4 Brand Dynamics
    • Brand Analysis By Indication
    • Solid Tumors Versus Hematological Malignancies
    • Current Market Assessment
    • Future Market Assessment
  • Analysis Of Brand By Number Of Approved Indications
    • Cytotoxic Therapies Are The Leading Class Of Brand In Terms Of The Number Of Approved Indications
  • Analysis Of Indication By Number Of Cancer Therapy Brands In The Top
    • Breast Cancer Is The Dominant Indication In Terms Of The Number Of Approved Agents In The Top 20 Cancer Therapy Brands
    • Brand Analysis By Mode Of Administration
    • Current Market Assessment
    • Future Market Assessment
    • Brand Analysis By Company
    • A Total Of 30 Companies Are Involved In The Marketing Of The Top 20 Cancer Brands In The Seven Major Markets
    • Astrazeneca And Roche Are The Leading Companies In Terms Of The Number Of Marketed Top 20 Cancer Brands
    • Roche Is Firmly Established As The Leading Company In The Oncology Market
    • Astrazeneca's Oncology Portfolio Is Set To Experience The Negative Impact Of Patent Expiry On All Of Its Key Products Over The Next 5 Years
    • Co-Marketed Cancer Therapy Brands Had The Largest Market Share In 2007
    • Brand Analysis By Event
    • Avastin Will Experience The Greatest Number Of Forecast Events Across The Seven Major Markets
    • Top 20 Brands Versus Rest Of Market Snapshot
    • Seven Major Markets
    • Us
    • Japan
    • 5eu
  • Chapter 5 Brand Profiles And Forecasts
    • Abraxane (Paclitaxel, Albumin-Bound Formulation; Abraxis/Astrazeneca/Taiho)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Next Generation Taxane Set To Enter The Eu Markets
    • Alimta (Pemetrexed; Eli Lilly)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Line Extensions And Horizontal Expansion Will Boost Alimta's Sales Over The Forecast Period
    • Arimidex (Anastrozole; Astrazeneca)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Arimidex Set To Maintain Its Blockbuster And Gold-Standard Status Despite Patent Expiry
    • Aromasin (Exemestane; Pfizer)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Aromasin Fails To Match Its Competitors In-Class, Although Its Alternative Mechanism Of Action Presents Some Opportunity
    • Avastin (Bevacizumab; Genentech/Roche/Chugai)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Avastin Set To Become The Biggest-Selling Targeted Therapy Cancer Brand In The Seven Major Markets In 2009
    • Camptosar (Irinotecan; Yakult Honsha/Daiichi Seiyaku)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Increased Generic Competition Decreases Sales Across The Seven Major Markets
    • Casodex (Bicalutamide; Astrazeneca)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Upcoming Patent Expiries Set To Hamper Sales Of This Class-Leading Brand
    • Dacogen (Decitabine; Eisai/Johnson & Johnson)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Anticipated High Uptake Set To Make Dacogen A Leading Cytotoxic Therapy Cancer Brand
    • Doxil (Pegylated Liposomal Doxorubicin; Johnson & Johnson/ Schering-Plough)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Ellence (Epirubicin; Pfizer/Kyowa Hakko Kogyo)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Eloxatin (Oxaliplatin; Sanofi-Aventis)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Top-Seller Likely To Face Strong Generic Competition
    • Erbitux (Cetuximab; Imclone/Bristol-Myers Squibb/Merck Serono)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Erbitux Seven Major Market Sales Passed $1 Billion In 2007 And Are Set For Modest Growth Through Line Extensions And New Approvals
    • Femara (Letrozole; Novartis/Chugai)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Final Results From Face Trial Could Indicate Definitive Superiority For Femara Over Arimidex
    • Furtulon (Doxifluridine; Roche/Chugai)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Gemzar (Gemcitabine; Eli Lilly)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Blockbuster Sales Set To Be Dented By Generic Entry
    • Gleevec (Imatinib; Novartis)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Patent Expiries Across The Seven Major Markets Will Curb Long-Term Growth Of Gleevec Sales
    • Herceptin (Trastuzumab; Genentech/Roche/Chugai)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Herceptin Well Placed To Maintain Strong Performance In Breast Cancer Market
    • Iressa (Gefitinib; Astrazeneca)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Iressa's Declining Sales Could Experience A Turnaround Following New Phase Iii Lung Cancer Trial
    • Ixempra (Ixabepilone; Bristol-Myers Squibb)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Launch In Big Indication Presents Opportunity For Novel Mitotic Inhibitor
    • Lupron (Leuprorelin; Takeda/Abbott/Tap/Wyeth)
    • Brand Profile
    • Brand Forecast Events*
    • Brand Forecast To 2017
    • Lupron's Lifecycle Has Been Extended By The Launch Of Various Formulations
    • Nexavar (Sorafenib; Onyx/Bayer Schering)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Liver Cancer Approval Will Help Nexavar To Make Up For Disappointing Performance In Rcc Market
    • Nolvadex (Tamoxifen; Astrazeneca)
    • Brand Profile
    • Brand Forecast Events*
    • Brand Forecast To 2017
    • Advent Of Aromatase Inhibitors And High Generic Competition Continues To Threaten Brand Sales
    • Revlimid (Lenalidomide; Celgene)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • First-Line Multiple Myeloma Approval Will Allow Revlimid To Reach Sales Of $1 Billion In The Seven Major Markets By 2015
    • Rituxan (Rituximab; Biogen Idec/Genentech/Roche/Zenyaku Kogyo)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Rituxan Was The Biggest-Selling Targeted Therapy Cancer Brand In 2007
    • Sprycel (Dasatinib; Bristol-Myers Squibb)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Generic Imatinib And Competition From Tasigna Will Limit Sprycel's Uptake In First-Line Cml
    • Suprefact (Buserelin; Sanofi-Aventis)
    • Brand Profile
    • Brand Forecast Events*
    • Brand Forecast To 2017
    • Sutent (Sunitinib; Pfizer)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Indication Expansion Will Enable Sutent To Become The Leading Small Molecule Targeted Therapy Cancer Brand In 2017
    • Tarceva (Erlotinib; Osi/Genentech/Roche/Chugai)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Additional Lung Cancer Approvals Will Help Drive Growth Of Tarceva Sales
    • Tasigna (Nilotinib; Novartis)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Tasigna Is Well-Positioned To Compensate For Gleevec Patent Expiry
    • Taxol (Paclitaxel; Bristol-Myers Squibb)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Taxotere (Docetaxel; Sanofi-Aventis)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Approval In New Indications And Extensive Use In Major Tumor Types Means Blockbuster Status Will Be Maintained
    • Temodar (Temozolomide; Schering-Plough)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Thalomid (Thalidomide; Celgene)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Ts-1 (Tegafur + Gimeracil + Oteracil; Taiho/Sanofi-Aventis)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Tykerb (Lapatinib; Glaxosmithkline)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Breast Cancer Line Extensions Will Push Tykerb Sales Beyond $1.4 Billion In The Seven Major Markets By 2017
    • Uft (Tegafur + Uracil; Taiho/Merck Serono)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Vectibix (Panitumumab; Amgen/Takeda)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Vectibix Is Set To Lag Behind Erbitux And Avastin In The Colorectal Cancer Market
    • Velcade (Bortezomib; Takeda/Johnson & Johnson)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Velcade Seven Major Market Sales Will Reach $1 Billion By 2010 Following Approval For First-Line Multiple Myeloma
    • Vidaza (Azacitidine; Celgene/Nippon Shinyaku)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • Entry Into New Markets Will Help Boost Sales To Blockbuster Status
    • Xeloda (Capecitabine; Roche/Chugai)
    • Brand Profile
    • Brand Forecast Events
    • Brand Forecast To 2017
    • New Indications And Line Extensions Will Ensure Increasing Sales
    • Zoladex (Goserelin; Astrazeneca)
    • Brand Profile
    • Brand Forecast Events*
    • Brand Forecast To 2017
    • Despite Equivalent Clinical Efficacy To Lupron, Zoladex Remains The Second Best-Selling Lhrh Analog
  • Appendix A - Market Assumptions
    • Country-Specific Assumptions And Events
    • Effect Of Medicare Modernization Act In The Us
    • Biennial Price Cuts In Japan
    • Generic Erosion Assumptions
    • Data Definitions, Limitations And Assumptions
    • Standard Units
    • Japanese Market Data
    • Derivation Of Sales Forecasts And Pricing Trends
    • Forecasts
    • Forecast Methodology
  • Appendix B
    • Bibliography
    • Datamonitor Reports
  • List Of Tables
  • List Of Figures
    • Abbreviations
    • Report Methodology
    • About Datamonitor Healthcare
    • Disclaimer
    • List Of Figures
    • Figure 1: Individual Country Sales And Market Share Of All Cancer Therapy Brands In The Seven Major Markets, 2007
    • Figure 2: Percentage Contribution Of The Top 20 Cancer Therapy Brands To The Total Cancer Therapy Brands Market In The Seven Major Markets, 2007
    • Figure 3: Individual Country Total Sales And Market Share Of Their Respective Top 20 Cancer Therapy Brands In The Seven Major Markets, 2007
    • Figure 4: Total Seven Major Market Sales Of All Cancer Therapy Brands By Drug Class, 2007
    • Figure 5: Sales And Market Share Of The Top 20 Cancer Therapy Brands In The Seven Major Markets By Drug Class, 2007
    • Figure 6: Sales And Market Share Of The Top 10 Cancer Therapy Brands In The Seven Major Markets, 2007
    • Figure 7: Total Forecast Sales Of Cancer Therapy Brands By Country In The Seven Major Markets, 2007-2017
    • Figure 8: Total Forecast Sales And Market Share Of Cancer Therapy Brands By Country, 2017
    • Figure 9: Forecast Percentage Contribution Of The Top 20 Cancer Therapy Brands To The Total Cancer Therapy Brands Market In The Seven Major Markets, 2017
    • Figure 10: Individual Country Total Forecast Sales And Market Share Of Their Respective Top 20 Cancer Therapy Brands Across The Seven Major Markets, 2017
    • Figure 11: Total Seven Major Market Forecast Sales Of All Cancer Therapy Brands By Drug Class, 2007-2017
    • Figure 12: Total Seven Major Market Forecast Sales And Market Share Of All Cancer Therapy Brands By Drug Class, 2017
    • Figure 13: Forecast Sales And Market Share Of The Top 20 Cancer Therapy Brands In The Seven Major Markets By Drug Class, 2017
    • Figure 14: Forecast Sales And Market Share Of The Top 10 Cancer Therapy Brands In The Seven Major Markets, 2017
    • Figure 15: Seven Major Market Population Aged 60 And Over, 2000-2050
    • Figure 16: Forecast Incidence Of Cancer Across The Seven Major Pharmaceutical Markets, 2001-2015
    • Figure 17: Global Therapy Sales ($M), 2007-2012
    • Figure 18: Us Sales Of All Cancer Therapy Brands By Drug Class, 2007
    • Figure 19: Sales Of The Top 20 Cancer Therapy Brands In The Us By Drug Class, 2007
    • Figure 20: Sales And Market Share Of The Top 10 Cancer Therapy Brands In The Us, 2007
    • Figure 21: Us Total Forecast Sales Of All Cancer Therapy Brands By Drug Class, 2007-2017
    • Figure 22: Us Total Forecast Sales And Market Share Of All Cancer Therapy Brands By Drug Class, 2017
    • Figure 23: Forecast Sales And Market Share Of The Top 20 Cancer Therapy Brands In The Us By Drug Class, 2017
    • Figure 24: Forecast Sales And Market Share Of The Top 10 Cancer Therapy Brands In The Us, 2017
    • Figure 25: Japan Sales Of All Cancer Therapy Brands By Drug Class, 2007
    • Figure 26: Sales Of The Top 20 Cancer Therapy Brands In Japan By Drug Class, 2007
    • Figure 27: Sales And Market Share Of The Top 10 Cancer Therapy Brands In Japan, 2007
    • Figure 28: Japan Total Forecast Sales Of All Cancer Therapy Brands By Drug Class, 2007-2017
    • Figure 29: Japan Total Forecast Sales And Market Share Of All Cancer Therapy Brands By Drug Class, 2017
    • Figure 30: Forecast Sales And Market Share Of The Top 20 Cancer Therapy Brands In Japan By Drug Class, 2017
    • Figure 31: Forecast Sales And Market Share Of The Top 10 Cancer Therapy Brands In Japan, 2017
    • Figure 32: 5eu Sales Of All Cancer Therapy Brands By Drug Class, 2007
    • Figure 33: Sales Of The Top 20 Cancer Therapy Brands In The 5eu By Drug Class, 2007
    • Figure 34: Sales And Market Share Of The Top 10 Cancer Therapy Brands In The 5eu, 2007
    • Figure 35: 5eu Total Forecast Sales Of All Cancer Therapy Brands By Drug Class, 2007-2017
    • Figure 36: 5eu Total Forecast Sales And Market Share Of All Cancer Therapy Brands By Drug Class, 2017
    • Figure 37: Forecast Sales And Market Share Of The Top 20 Cancer Therapy Brands In The 5eu By Drug Class, 2017
    • Figure 38: Forecast Sales And Market Share Of The Top 10 Cancer Therapy Brands In The 5eu, 2017
    • Figure 39: France Sales Of All Cancer Therapy Brands By Drug Class, 2007
    • Figure 40: Sales Of The Top 20 Cancer Therapy Brands In France By Drug Class, 2007
    • Figure 41: Sales And Market Share Of The Top 10 Cancer Therapy Brands In France, 2007
    • Figure 42: France Total Forecast Sales Of All Cancer Therapy Brands By Drug Class, 2007-2017
    • Figure 43: France Total Forecast Sales And Market Share Of All Cancer Therapy Brands By Drug Class, 2017
    • Figure 44: Forecast Sales And Market Share Of The Top 20 Cancer Therapy Brands In France By Drug Class, 2017
    • Figure 45: Forecast Sales And Market Share Of The Top 10 Cancer Therapy Brands In France, 2017
    • Figure 46: Germany Sales Of All Cancer Therapy Brands By Drug Class, 2007
    • Figure 47: Sales Of The Top 20 Cancer Therapy Brands In Germany By Drug Class, 2007
    • Figure 48: Sales And Market Share Of The Top 10 Cancer Therapy Brands In Germany, 2007
    • Figure 49: Germany Total Forecast Sales Of All Cancer Therapy Brands By Drug Class, 2007-2017
    • Figure 50: Germany Total Forecast Sales And Market Share Of All Cancer Therapy Brands By Drug Class, 2017
    • Figure 51: Forecast Sales And Market Share Of The Top 20 Cancer Therapy Brands In Germany By Drug Class, 2017
    • Figure 52: Forecast Sales And Market Share Of The Top 10 Cancer Therapy Brands In Germany, 2017
    • Figure 53: Italy Sales Of All Cancer Therapy Brands By Drug Class, 2007
    • Figure 54: Sales Of The Top 20 Cancer Therapy Brands In Italy By Drug Class, 2007
    • Figure 55: Sales And Market Share Of The Top 10 Cancer Therapy Brands In Italy, 2007
    • Figure 56: Italy Total Forecast Sales Of All Cancer Therapy Brands By Drug Class, 2007-2017
    • Figure 57: Italy Total Forecast Sales And Market Share Of All Cancer Therapy Brands By Drug Class, 2017
    • Figure 58: Forecast Sales And Market Share Of The Top 20 Cancer Therapy Brands In Italy By Drug Class, 2017
    • Figure 59: Forecast Sales And Market Share Of The Top 10 Cancer Therapy Brands In Italy, 2017
    • Figure 60: Spain Sales Of All Cancer Therapy Brands By Drug Class, 2007
    • Figure 61: Sales Of The Top 20 Cancer Therapy Brands In Spain By Drug Class, 2007
    • Figure 62: Sales And Market Share Of The Top 10 Cancer Therapy Brands In Spain, 2007
    • Figure 63: Spain Total Forecast Sales Of All Cancer Therapy Brands By Drug Class, 2007-2017
    • Figure 64: Spain Total Forecast Sales And Market Share Of All Cancer Therapy Brands By Drug Class, 2017
    • Figure 65: Forecast Sales And Market Share Of The Top 20 Cancer Therapy Brands In Spain By Drug Class, 2017
    • Figure 66: Forecast Sales And Market Share Of The Top 10 Cancer Therapy Brands In Spain, 2017
    • Figure 67: Uk Sales Of All Cancer Therapy Brands By Drug Class, 2007
    • Figure 68: Sales Of The Top 20 Cancer Therapy Brands In The Uk By Drug Class, 2007
    • Figure 69: Sales And Market Share Of The Top 10 Cancer Therapy Brands In The Uk, 2007
    • Figure 70: Uk Total Forecast Sales Of All Cancer Therapy Brands By Drug Class, 2007-2017
    • Figure 71: Uk Total Forecast Sales And Market Share Of All Cancer Therapy Brands By Drug Class, 2017
    • Figure 72: Forecast Sales And Market Share Of The Top 20 Cancer Therapy Brands In The Uk By Drug Class, 2017
    • Figure 73: Forecast Sales And Market Share Of The Top 10 Cancer Therapy Brands In The Uk, 2017
    • Figure 74: Us, Japan, 5eu And Row Total Cancer Therapy Sales And Market Share, 2007
    • Figure 75: Us, Japan, 5eu And Row Antihormonal Cancer Therapy Sales And Market Share, 2007
    • Figure 76: Us, Japan, 5eu And Row Cytotoxic Therapy Sales And Market Share, 2007
    • Figure 77: Us, Japan, 5eu And Row Targeted Cancer Therapy Sales And Market Share, 2007
    • Figure 78: Seven Major Market Sales Of All Cancer Therapy Brands By Type Of Indication, 2007
    • Figure 79: Sales Of The Top 20 Cancer Therapy Brands In The Seven Major Markets By Type Of Indication, 2007
    • Figure 80: Forecast Seven Major Market Sales Of All Cancer Therapy Brands By Type Of Indication, 2017
    • Figure 81: Forecast Sales Of The Top 20 Cancer Therapy Brands In The Seven Major Markets By Type Of Indication, 2017
    • Figure 82: Analysis Of Brands Included In The Top 20 Cancer Therapy Brands In 2007 Or 2017 By Number Of Approved Oncology Indications
    • Figure 83: Analysis Of Oncology Indications By Number Of Approved Brands Included In The Top 20 Cancer Therapy Brands In 2007 Or 2017
    • Figure 84: Seven Major Market Sales Of All Cancer Therapy Brands By Mode Of Administration, 2007
    • Figure 85: Sales Of Top 20 Cancer Therapy Brands In The Seven Major Markets By Mode Of Administration, 2007
    • Figure 86: Forecast Seven Major Market Sales Of All Cancer Therapy Brands By Mode Of Administration, 2017
    • Figure 87: Forecast Sales Of The Top 20 Cancer Therapy Brands In The Seven Major Markets By Mode Of Administration, 2017
    • Figure 88: Analysis Of Companies By Number Of Cancer Therapy Brands Included In The Top 20 In 2007 Or 2017
    • Figure 89: Seven Major Market Sales Of All Cancer Therapy Brands Marketed By Single Companies Versus Sales Of All Cancer Therapy Brands Marketed By More Than One Company, 2007
    • Figure 90: Seven Major Market Sales Of Top 20 Cancer Therapy Brands Marketed By Single Companies Versus Sales Of Top 20 Cancer Therapy Brands Marketed By More Than One Company, 2007
    • Figure 91: Analysis Of Top 20 Cancer Therapy Brands By Number Of Forecast Events, 2008-2017
    • Figure 92: Seven Major Market Volume And Value Sales By Drug Class For The Top 20 Brands Compared To The Rest Of The Market, 2007
    • Figure 93: Us Volume And Value Sales By Drug Class For The Top 20 Brands Compared To The Rest Of The Market, 2007
    • Figure 94: Japan Volume And Value Sales By Drug Class For The Top 20 Brands Compared To The Rest Of The Market, 2007
    • Figure 95: 5eu Volume And Value Sales By Drug Class For The Top 20 Brands Compared To The Rest Of The Market, 2007

Buy now >>

Stumble it!

To top